

Identification and Management of Sexual Transmitted Infections

Kay Roussos-Ross, MD

Professor

Chief, Division Academic Specialist in General Obstetrics and Gynecology

Department of Obstetrics and Gynecology

University of Florida College of Medicine

Gainesville, FL



1

Disclosure

I have no financial interests or relationships to disclose.



2

TOPICS OF DISCUSSION

Sexually Transmitted Infections:

Chlamydia

Gonorrhea

HPV

Syphilis

Herpes

3

LEARNING OBJECTIVES

- ☐ Pathophysiology of infection
- ☐ Clinical manifestations
- ☐ Diagnosis
- ☐ Treatment

4

CHLAMYDIA

- ❑ Pathogen - *Chlamydia trachomatis*
- ❑ Obligate intracellular parasite
 - ❑ Dependent on host cell for energy production
- ❑ Can only be grown in tissue culture

5

CHLAMYDIA MICROBIOLOGY

Reticular body

Elementary body – infectious form

Two key virulence factors

- Enhanced ingestion by host cells
- Inhibition of phagolysosomal fusion

6

CHLAMYDIA: MECHANISMS OF TRANSMISSION

- Sexual contact
- Perinatal

7

CHLAMYDIA FREQUENCY

- Most common STI in Western countries
- 3 - 5 x as common as gonorrhea
- Prevalence varies with the population

8

CHLAMYDIA CLINICAL MANIFESTATIONS IN MEN

- Urethritis
- Proctitis
- Epididymitis



9

CHLAMYDIA CLINICAL MANIFESTATIONS IN WOMEN

- Urethritis
- Endocervicitis
- PID
- Perihepatitis – Fitz-Hugh-Curtis Syndrome



10

FITZ-HUGH-CURTIS SYNDROME



11

CHLAMYDIA DIAGNOSIS

- Clinical examination
- Culture
- Nucleic acid amplification test (NAAT)
 - Urine
 - Cervical discharge

12

CHLAMYDIA TREATMENT

Patient and partner should be treated

Risk Category	Recommended Regimen	Alternatives
Adults and adolescents	doxycycline 100 mg orally 2x/day for 7 days	azithromycin 1 gm orally in a single dose OR levofloxacin 500 mg orally 1x/day for 7 days
Pregnancy	azithromycin 1 gm orally in a single dose	amoxicillin 500 mg orally 3x/day for 7 days

13

CHLAMYDIA SEQUELAE

- ☐ Infertility
- ☐ Ectopic pregnancy
- ☐ Chronic pelvic pain

14

GONORRHEA MICROBIOLOGY

Pathogen – *Neisseria gonorrhoea*
Gram-negative diplococcus
Can be cultured in selective media



15

GONORRHEA MECHANISMS OF TRANSMISSION

Sexual contact
Perinatal

16

GONORRHEA FREQUENCY

- ❑ Less common than chlamydia
- ❑ Prevalence varies with population

17

GONORRHEA CLINICAL MANIFESTATIONS IN MEN

- ❑ Urethritis
- ❑ Epididymitis
- ❑ Proctitis
- ❑ Pharyngitis

18

GONORRHEA CLINICAL PRESENTATION



19

GONORRHEA CLINICAL MANIFESTATIONS IN WOMEN

- ☐ Urethritis
- ☐ Endocervicitis
- ☐ Proctitis
- ☐ PID
- ☐ Pharyngitis



20

GONORRHEA DISSEMINATED INFECTION

- ☐ Arthritis
- ☐ Dermatitis
- ☐ Pericarditis and endocarditis
- ☐ Meningitis
- ☐ Perihepatitis

21

DISSEMINATED GONORRHEA CLINICAL PRESENTATION




22

GONORRHEA DIAGNOSIS

- ☐ Clinical examination
- ☐ Gram stain
- ☐ Culture
- ☐ Nucleic acid amplification test (NAAT)
 - ☐ Urine
 - ☐ Cervical discharge

23

GONORRHEA GRAM STAIN



24

GONORRHEA TREATMENT

Patient and partner should be treated

Risk Category	Recommended Regimen	Alternatives
Uncomplicated infections of the cervix, urethra, and rectum: adults and adolescents <150 kg ⁶	ceftriaxone 500 mg IM in a single dose ¹⁷	If cephalosporin allergy: gentamicin 240 mg IM in a single dose PLUS azithromycin 2 gm orally in a single dose If ceftriaxone administration is not available or not feasible: cefixime 800 mg orally in a single dose ¹⁷
Uncomplicated infections of the pharynx: adults and adolescents <150 kg ⁶	ceftriaxone 500 mg IM in a single dose ¹⁷	
Pregnancy	ceftriaxone 500 mg IM in a single dose ¹⁷	
Conjunctivitis	ceftriaxone 1 gm IM in a single dose ¹⁸	
Disseminated gonococcal infections (DGI) ¹⁹	ceftriaxone 1 gm IM or by IV every 24 hours ¹⁷	cefotaxime 1 gm by IV every 8 hours OR cefizoxime 1 gm every 8 hours

25

GONORRHEA SEQUELAE

- ☐ Infertility
- ☐ Ectopic pregnancy
- ☐ Chronic pelvic pain

26

MYCOPLASMA GENITALIUM

- ❑ Pathogen – *Mycoplasma Genitalium*
- ❑ Lacks a cell wall
- ❑ Slow growing in culture (can take up to 6 months)

27

MYCOPLASMA: MECHANISMS OF TRANSMISSION

- ❑ Sexual contact

28

MYCOPLASMA

□ Men-

- symptomatic and asymptomatic urethritis

□ Women-

- cervicitis
- PID
- preterm delivery
- spontaneous abortion
- infertility

29

MYCOPLASMA DIAGNOSIS

□ Who to test?

- Those with recurrent urethritis, cervicitis
 - Possibly those with PID

□ Diagnosis

- NAAT
 - urine and urethral, penile meatal, endocervical, and vaginal swab samples

30

MYCOPLASMA

- Antibiotic resistance
 - Recommend against one dose azithromycin
 - ***pregnancy*** current recommendation is still azithromycin

31

MYCOPLASMA TREATMENT OPTIONS

Recommended Regimens if *M. genitalium* Resistance Testing is Available

If *macrolide sensitive*: **Doxycycline** 100 mg orally 2 times/day for 7 days, followed by **azithromycin** 1 g orally initial dose, followed by 500 mg orally once daily for 3 additional days (2.5 g total)

If *macrolide resistant*: **Doxycycline** 100 mg orally 2 times/day for 7 days followed by **moxifloxacin** 400 mg orally once daily for 7 days

Recommended Regimens if *M. genitalium* Resistance Testing is Not Available

If *M. genitalium* is detected by an FDA-cleared NAAT: **Doxycycline** 100 mg orally 2 times/day for 7 days, followed by **moxifloxacin** 400 mg orally once daily for 7 days

32

HUMAN PAPILLOMA VIRUS

Over 120 HPV types:

- >40 infect the mucosa
 - 6, 11 – “genital warts”
 - 16, 18, 31, 33, 45 – “high risk for cervical cancer”



Transmission:

- Direct contact
- Autoinoculation
- ↑ in immunosuppressed patients

33

HPV: HISTOPATHOLOGY “WARTS”

- Epidermal hyperplasia and papillomatosis
- Hyperkeratosis and parakeratosis
- Koilocytes



34

HPV-CONDYLOMA ACUMINATA ANOGENITAL WARTS

- Discrete, papillomatous, exophytic papules
- Sessile or pedunculated
- May form confluent plaques
- Lack the thick horny scale found on cutaneous warts



35

CONDYLOMA TREATMENT


Risk Category	Recommended Regimen	Alternatives
External anogenital warts ¹²	Patient-applied	
	imiquimod 3.75% or 5% ¹³ cream	
	OR podofilox 0.5% solution or gel	
	OR sinecatechins 15% ointment ¹³	
	Provider-administered	
	cryotherapy with liquid nitrogen or cryoprobe	
	OR surgical removal either by tangential scissor excision, tangential shave excision, curettage, laser, or electrosurgery	
	OR trichloroacetic acid (TCA) or bichloroacetic acid (BCA) 80%–90% solution	
Urethral meatus warts	cryotherapy with liquid nitrogen	
	OR surgical removal	
Vaginal warts ¹⁴	cryotherapy with liquid nitrogen	
	OR surgical removal	
	OR TCA or BCA 80%–90% solution	

36

HPV: INTRAEPITHELIAL NEOPLASIA

- Persistent infection with high-risk HPV types represents the most important risk factor for the development of neoplasia
- Cervix, vulva, vagina, penis and anus

Full-thickness atypia
Abnormal keratinocyte
maturation
Nuclear pleomorphism
Dyskeratosis



37

HPV VACCINES

Helps protect against HPV responsible for genital warts and HPV-related genital cancer

- Cervical, vaginal, vulvar, penile, anal, oropharyngeal
 - FDA-approved and CDC-recommended up to age 45
 - Pre-teen boys and girls – 11-12 yo (can start at 9 yo)

Series of 3 doses over 6mo

- If vaccine started before 15 yo only need 2 doses
 - Injection site reaction – most common side effect

38

HPV VACCINES

Gardasil 9

- 2014 – FDA-approved
- HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58

Gardasil

- 2006 – FDA-approved
- HPV 6, 11, 16, and 18

Cervarix

- 2009 – FDA-approved for women and girls
- HPV 16 and 18

39

HERPES SIMPLEX VIRUS

HSV1 and HSV2

Transmission:

- **Direct contact –**
 - mucous membranes or open skin
 - perinatal
- **Intrauterine – rare**
- **HIV-HSV co-infection:**
 - ↑risk of transmission

40

HSV: CLINICAL

Primary disease:

- More severe than recurrent
 - painful ulcerations

Recurrent disease:

- Milder; prodrome of pain, itching, tingling, paresthesia

Exam:

- Grouped vesicles on an erythematous base
- Round erosions with scalloped borders
- Locations: penis, perineum, anus, female external genitalia, cervix






41

HSV: HISTOPATHOLOGY

- Acantholysis and intraepidermal vesicles
- Ulcer lesions - keratinocyte necrosis and loss of epidermis
- Neutrophilic and lymphocytic inflammation

Ulcer

Keratinocyte
necrosis and
vesicle

42

HSV TREATMENT

Risk Category	Recommended Regimen	Alternatives
First clinical episode of genital herpes ⁷	acyclovir 400 mg orally 3x/day for 7–10 days ^a OR famciclovir 250 mg orally 3x/day for 7–10 days OR valacyclovir 1 gm orally 2x/day for 7–10 days	
Suppressive therapy for recurrent genital herpes (HSV-2)	acyclovir 400 mg orally 2x/day OR valacyclovir 500 mg orally 1x/day ^a OR valacyclovir 1 gm orally 1x/day OR famciclovir 250 mg orally 2x/day	
Episodic therapy for recurrent genital herpes (HSV-2) ¹⁰	acyclovir 800 mg orally 2x/day for 5 days OR acyclovir 800 mg orally 3x/day for 2 days OR famciclovir 1 gm orally 2x/day for 1 day OR famciclovir 500 mg orally once, FOLLOWED BY 250 mg 2x/day for 2 days OR famciclovir 125 mg orally 2x/day for 5 days OR valacyclovir 500 mg orally 2x/day for 3 days OR valacyclovir 1 gm orally 1x/day for 5 days	
Daily suppressive therapy of recurrent genital herpes in pregnant women ¹¹	acyclovir 400 mg orally 3x/day OR valacyclovir 500 mg orally 2x/day	

43

SYPHILIS MICROBIOLOGY



☐ Pathogen - *Treponema pallidum*

☐ Cannot be cultivated in vitro

44

SYPHILIS FREQUENCY

- Incidence has increased , especially in females aged 15-24 years
- Highest prevalence - urban blacks and hispanics

45

SYPHILIS EPIDEMIOLOGY

- In 2020 the CDC recorded 133,945 cases of syphilis, a 6.8% increase from 2019
- In that same year, the CDC documented 2148 cases of congenital syphilis
 - 149 cases resulted in stillbirths or neonatal deaths

46

SYPHILIS MECHANISMS OF TRANSMISSION

- Sexual contact
 - Highly contagious
 - 50-60% of partners become infected after a single unprotected exposure
- Perinatal

47

SYPHILIS CLASSIFICATION

- Primary
- Secondary
- Latent
 - Early
 - Late
 - Indeterminate
- Tertiary
- Neurosyphilis



48

SYPHILIS DIAGNOSIS

Clinical examination

Darkfield microscopy – rarely used

Serology – mainstay of diagnosis

- VDRL or RPR – screening test
- MHA or FTA – confirmatory test
- IgM and IgG

49

SYPHILIS CONVENTIONAL SEROLOGY

TEST	RESPONSE AFTER TREATMENT
VDRL or RPR	Reverts to negative or decreases to a very low titer Significant elevation in titer indicates re-infection
MHA or FTA	Remains positive for lifetime of patient
<u>IgM</u>	Indicative of acute infection
<u>IgG</u>	Indicative of chronic infection

50

DIAGNOSIS OF SYPHILIS REVERSE SEQUENCE ALGORITHM

T. pallidum antibody



RPR or VDRL



T. pallidum particle
agglutination test

51

DIAGNOSIS OF SYPHILIS REVERSE SEQUENCE ALGORITHM

- Initial screening test → *T. pallidum* antibody
- If negative → patient is uninfected
- If positive → reflex RPR
- If RPR is positive → past or present infection is confirmed
- If RPR is negative → *T. pallidum* particle agglutination test (TP-PA)
 - If positive → past or present infection is confirmed
 - If negative → consider uninfected (false positive)

52

PRIMARY SYPHILIS PRINCIPAL CLINICAL FINDING

Painless
chancre



53

SECONDARY SYPHILIS PRINCIPAL CLINICAL FINDINGS

Condyloma
lata



54

SECONDARY SYPHILIS PRINCIPAL CLINICAL FINDINGS

Rash on palms
and soles



55

SECONDARY SYPHILIS CLINICAL FINDINGS

Mucous
Patches



56

LATE-STAGE SYPHILIS PRINCIPAL CLINICAL MANIFESTATIONS

Destructive gummas

Aortic valve injury

CNS manifestations

- Dementia
- Tabes dorsalis
- Pupillary abnormalities

57

ARGYLL-ROBERTSON PUPIL

Accommodates
but does not
react



58

LATE STAGE SYPHYLIS GUMMAS



59

CONGENITAL SYPHILIS CLINICAL MANIFESTATIONS

Fetal death

Growth restriction

Multiple anomalies

- Immediately apparent at birth
- Delayed appearance

60

CONGENITAL SYPHILIS ABNORMAL DENTITION

Hutchinson's
Teeth



61

CONGENITAL SYPHILIS SABER SHINS



62

SYPHILIS TREATMENT

Patient and sexual partner(s) should be treated

Antibiotic therapy

- Penicillin – preferred in pregnancy because of proven value in treating fetal infection
- Doxycycline – contraindicated in pregnancy
- Tetracycline – contraindicated in pregnancy
- Ceftriaxone

63

SYPHILIS ANTIBIOTIC TREATMENT

Risk Category	Recommended Regimen	Alternatives
Primary, secondary, and early latent: adults (including pregnant women and people with HIV infection)	benzathine penicillin G 2.4 million units IM in a single dose	
Late latent adults (including pregnant women and people with HIV infection)	benzathine penicillin G 7.2 million units total, administered as 3 doses of 2.4 million units IM each at 1-week intervals	
Neurosyphilis, ocular syphilis, and otosyphilis	aqueous crystalline penicillin G 18–24 million units per day, administered as 3–4 million units by IV every 4 hours or continuous infusion, for 10–14 days	procaine penicillin G 2.4 million units IM 1x/day PLUS probenecid 500 mg orally 4x/day, both for 10–14 days

64

ACKNOWLEDGEMENTS

- I would like to acknowledge and thank Dr. Duff and Dr. Merkel for use of their slides